Welcome to our dedicated page for MiMedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on MiMedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a pioneer in the field of advanced wound care and therapeutic biologics. The company specializes in developing and distributing human placental tissue allografts utilizing patent-protected processes. With a cornerstone methodology known as the PURION® Process, MiMedx ensures the production of high-quality allografts via aseptic processing techniques and terminal sterilization.
Having supplied over two million allografts through direct and consignment shipments, MiMedx is a trusted name in the healthcare sector. The company’s product range includes EpiFix for external use and AmnioFix for internal applications, alongside other innovative products such as AmnioCord, AmnioFill, EpiBurn, and EpiCord. Additionally, MiMedx markets allografts for ophthalmic surgery and dental applications through third-party licenses.
MiMedx is dedicated to transforming wound care in sectors like burn treatment, surgical procedures, sports medicine, and orthopedics. By combining its extensive portfolio with strategic initiatives, such as its recent exclusive partnership with Regenity for a 510(k) cleared, bovine-derived collagen matrix, the company aims to enhance its competitive edge and expand its market reach.
Financially, MiMedx has shown impressive growth. For 2023, the company reported net sales of $321 million, reflecting a 20% increase from the previous year. Strategically, new credit facilities have been secured to bolster financial flexibility. The company expects low double-digit net sales growth for 2024 and an adjusted EBITDA margin exceeding 20%.
Despite facing regulatory challenges, such as the FDA’s stance on the AXIOFILL product, MiMedx continues to thrive. The company is actively engaging with the FDA while maintaining the product in the market. This resilience underscores MiMedx’s commitment to compliance and innovation in providing safe and effective products.
The company’s vision is to be the leading global provider of healing solutions through relentless innovation, aiming to restore quality of life for patients. For more information, visit www.mimedx.com.
MiMedx Group, Inc. (MDXG) has praised the Office of Inspector General's recommendation for the Centers for Medicare and Medicaid Services (CMS) to expedite addressing issues related to Average Sales Price (ASP) reporting for skin substitute products. The OIG report highlights non-compliance from some manufacturers, impacting Medicare spending in private physician settings. MiMedx's products, EPIFIX® and EPICORD®, have been sold under transparent ASP-based rates, promoting equitable patient care. The report also encourages CMS to consider effective payment approaches and ensure compliance from manufacturers as a way to alleviate financial burdens on the Medicare Trust Fund.
MiMedx Group reported its highest quarterly net sales since Q4 2019, achieving $74.4 million in Q4 2022, a 10.3% increase year-over-year. For the full year, net sales reached $267.8 million, up 3.6%. Despite strong sales, the company faced a net loss of $0.4 million in Q4, compared to a net income of $2.2 million in the prior year. The gross margin decreased to 80.7% from 84.0%. MiMedx initiated its first registrational clinical trial for mDHACM targeting knee osteoarthritis, emphasizing growth potential in the Wound & Surgical segments. Future growth may depend on Medicare reimbursement changes.
MiMedx Group (Nasdaq: MDXG) will report its fourth quarter and full year financial results for the period ending December 31, 2022 after the market closes on February 28, 2023. A conference call and webcast led by the senior management team will follow at 5:00 p.m. ET on the same day to discuss the results.
The company is a leader in placental biologics, focusing on various healthcare sectors like Advanced Wound Care and knee osteoarthritis treatments. MiMedx has successfully supplied over two million allografts using its proprietary PURION® process.
MIMEDX (Nasdaq: MDXG) announced the appointment of Joseph H. Capper as its new Chief Executive Officer, effective immediately. Capper brings nearly 30 years of experience in MedTech, previously leading BioTelemetry through a successful turnaround that resulted in a $2.8 billion acquisition. The Board of Directors expressed confidence in Capper's leadership, citing his track record of delivering results. As part of his inducement package, he will receive 3.3 million performance stock units and 3.6 million stock options with an exercise price of $3.70. MIMEDX aims to leverage its innovative placental biologics for future growth.
Marietta, Ga., Jan. 09, 2023 – MiMedx Group (Nasdaq: MDXG) expects Q4 2022 net sales of $73M to $76M and full-year sales of $266M to $269M, unchanged since November 2022. The company commented on potential Medicare reimbursement changes impacting skin substitutes, accounting for 28% of sales, with 90% of these sales from EPIFIX. While uncertainties remain, MiMedx has taken steps to mitigate risks. Additionally, the company anticipates $5M in annual savings from recent restructuring and has entered a partnership for EPIFIX distribution in Japan.
MIMEDX has partnered with Gunze Medical to exclusively distribute EPIFIX in Japan, marking a significant move in the wound care market. This collaboration, announced on January 4, 2023, follows EPIFIX's regulatory approval and favorable reimbursement decision. Gunze Medical, backed by over 90 sales representatives, aims to leverage its existing clinician relationships to enhance awareness and sales. This partnership positions EPIFIX as the first and only amniotic tissue product approved in Japan for treating chronic wounds, targeting conditions like diabetic foot and venous leg ulcers.
MiMedx Group has appointed Ricci S. Whitlow as Chief Operating Officer, effective January 3, 2023. With over 30 years of experience in the MedTech industry, Whitlow is expected to enhance MIMEDX’s operational leadership in manufacturing, supply chain, and regulatory functions. Formerly President of Clinical Supply Services at Catalent, she aims to leverage her expertise to navigate complex regulatory changes and drive growth. Interim CEO Todd Newton emphasized the importance of this role for the company's future and its mission in placental biologics.
MiMedx Group, Inc. (Nasdaq: MDXG) has licensed exclusive rights to Turn Therapeutics’ antimicrobial technology, PermaFusion®, to enhance product development for wound and surgical recovery. This agreement aims to expedite the introduction of new biologic products, leveraging Turn's nanodroplet technology and antimicrobial properties. Furthermore, MiMedx is also acquiring commercial rights to Turn's FleX™ AM product, pending FDA clearance, expanding its portfolio in the wound care market.
Marietta, Ga., Nov. 10, 2022 – MiMedx Group (Nasdaq: MDXG), a placental biologics company, announced its participation in two upcoming investor conferences. Senior management will present at the Canaccord Genuity MedTech Forum on November 17, 2022, at 9:30 AM ET, and at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, also at 9:30 AM ET. Webcasts for both events will be available on the company's website. MiMedx specializes in developing and distributing placental tissue allografts for non-healing wounds and degenerative musculoskeletal conditions.
MiMedx Group reported third quarter net sales of $67.7 million, a 7.3% increase compared to the prior year. This growth was driven by the Surgical Recovery market and initial contributions from new products, AMNIOEFFECT™ and AXIOFILL™. However, the company also faced challenges, including a net loss of $8.4 million, up from $2.3 million the previous year. Operating expenses increased to $53.5 million, reflecting higher sales commissions and travel costs. Looking ahead, MiMedx anticipates fourth quarter sales of $73 to $76 million.
FAQ
What is the current stock price of MiMedx Group (MDXG)?
What is the market cap of MiMedx Group (MDXG)?
What does MiMedx Group, Inc. specialize in?
What are MiMedx's key products?
How has MiMedx performed financially in 2023?
What is the PURION® Process?
How does MiMedx handle regulatory challenges?
What new collaborations has MiMedx recently announced?
What is MiMedx's vision?
Where can I find more information about MiMedx?
What markets does MiMedx target?
Who can I contact for investor relations at MiMedx?
